Veränderungen von B-Zellantigenen unter Rituximab-Therapie:FMC7 ist Teil des CD20-Antigenkomplexes Maya Jordanova1.1234562.72.1.2.1.1.2.1.2.2.1.2.1.82.1.2.2.92.1.2.3.102.1.3.2.1.4.112.2.2.2.1.2.2.1.1.12132.2.1.2.142.2.1.3.152.2.1.4.2.2.1.5.162.2.1.6.17182.2.1.7.2.2.1.8.192.2.2.2.2.2.1.202.2.2.2.212.2.2.3.22232.2.2.4.2.3.243.253.1.3.1.1.3.1.1.1.26273.1.1.2.28293.1.2.303.1.2.1.313233343.1.2.2.35363.2.373.3.383.4.3.4.1.393.4.2.403.5.4.4142434445464748495051525.5354 Schriftenverzeichnis555657585960Erklärung an Eides StattDanksagungdeInhaltsverzeichnisHilfe Schriftenverzeichnis

(1) Garand R, Robillard N. Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications . Hematol Cell Ther 1996; 38(6): 471-486. (2) Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia 1996; 10(5): 877-895. (3) DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998; 25(1): 6-10. (4) Borowitz MJ, Bray R, Gascoyne R, Melnick S, Parker JW, Picker L et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry 1997; 30(5): 236-244. (5) Huh YO, Andreeff M. Flow cytometry. Clinical and research applications in hematologic malignancies. Hematol Oncol Clin North Am 1994; 8(4): 703-723. (6) Tefferi A, Bartholmai BJ, Witzig TE, Li CY, Hanson CA, Phyliky RL. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1996; 106 (4): 457-461. (7) Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40(4): 259-263. (8) Ginaldi L, De MM, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51(5): 364-369. (9) Witzig TE, Borell TJ, Herath JF, Tefferi A, Li CY, Jenkins RB. Detection of trisomy 12 by FISH in untreated B-chronic lymphocytic leukemia: correlation with stage and CD20 antigen expression intensity. Leuk Lymphoma 1994; 14(5-6): 447-451. (10) Witzig TE, Li CY, Tefferi A, Katzmann JA. Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1994; 101(3): 312-317. (11) D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di RN, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000; 64(4 ): 275-281. (12) Catovsky D, Cherchi M, Brookss D, Bradely J, Zola H. Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood 1981; 58(2): 406-408. (13) Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 1994; 101(3): 283-289. (14) den OG, Schuit HR, Waayer JL, Huibregtsen L, Hijmans W, Jansen J. Chronic B-cell leukemias: relation between morphological and immunological features. Clin Immunol Immunopathol 1985; 35(1): 92-102. (15) Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996; 92(2): 382-388. (16) Geisler CH, Philip P, Christensen BE, Hou-Jensen K, Pedersen NT, Jensen OM et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997; 21(11-12): 1011-1023. (17) Geisler CH, Larsen JK, Hansen NE, Hansen MM, Christensen BE, Lund B et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991; 78(7): 1795-1802. (18) Newman RA, Peterson B, Davey FR, Brabyn C, Collins H, Brunetto VL et al. Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1993; 82(4): 1239-1246. (19) Matutes E, Owusu-Ankomah K, Morilla R, Garcia MJ, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8(10): 1640-1645. (20) Brooks DA, Beckman IG, Bradley J, McNamara PJ, Thomas ME, Zola H. Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol 1981; 126(4): 1373-1377. (21) Zola H, Moore HA, Hohmann A, Hunter IK, Nikoloutsopoulos A, Bradley J. The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression. J Immunol 1984; 133(1): 321-326. (22) Zola H, Neoh SH, Potter A, Melo JV, De OM, Catovsky D. Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. Dis Markers 1987; 5(4): 227-235. (23) Bloem AC, Chand MA, Dollekamp I, Rijkers GT. Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7. J Immunol 1988; 140(3): 768-773. (24) Rijkers GT, Dollekamp I, Zegers BJ. Evidence that FMC7 is a human B cell differentiation antigen. Immunol Lett 1990; 24(4): 261-264. (25) Zola H. Human B cells: is FMC7 a marker for relatively mature B cells or does it define a population equivalent to the LyB5-negative mouse B cells?In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, editors. Leukocyte Typing II.

New York

: Springer, 1986: 141-145. (26) Zola H, McNamara PJ, Moore HA, Smart IJ , Brooks DA, Beckman IG et al. Maturation of human B lymphocytes--studies with a panel of monoclonal antibodies against membrane antigens. Clin Exp Immunol 1983; 52(3): 655-664. (27) Ferro LM, Zola H . Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro. Immunology 1990; 69(3): 373-378. (28) Hubl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry 1998; 34(2): 71-74. (29) D'hautcourt JL, Isaac J. Mean fluorescence intensity of dual stained cells. Cytometry 1999; 38(1): 44-46. (30) Kehrl JH, Riva A, Wilson GL, Thevenin C . Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 1994; 15(9): 432-436. (31) Tedder TF, Klejman G, Schlossman SF, Saito H. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol 1989; 142(7): 2560-2568. (32) Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7(3): 711-717. (33) Stamenkovic I, Seed B. Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein. J Exp Med 1988; 167(6): 1975-1980. (34) Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125(4): 1678-1685. (35) Tedder TF, Schlossman SF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem 1988; 263(20): 10009-10015. (36) Tedder TF, McIntyre G, Schlossman SF. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. Mol Immunol 1988; 25(12): 1321-1330. (37) Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273(1): 344-348. (38) Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995; 270(38): 22632-22638. (39) Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 1993; 151(9): 4494-4504. (40) Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989; 264(19): 11282-11287. (41) Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121(5): 1121-1132. (42) Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 1995; 270(22): 13099-13104. (43) Anderson RG. Caveolae: where incoming and outgoing messengers meet . Proc Natl Acad Sci U S A 1993; 90(23): 10909-10913. (44) Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387(6633): 569-572. (45) Parton RG, Simons K. Digging into caveolae. Science 1995; 269(5229): 1398-1399. (46) Polyak MJ, Tailor SH, Deans JP . Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998; 161(7): 3242-3248. (47) Whiting PJ. The GABA-A receptor gene family: new targets for therapeutic intervention. Neurochem Int 1999; 34(5): 387-390. (48) Field KA, Holowka D, Baird B. Compartmentalized activation of the high affinity immunoglobulin E receptor within membrane domains. J Biol Chem 1997; 272(7): 4276-4280. (49) Mayor S, Rothberg KG, Maxfield FR. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 1994; 264(5167): 1948-1951. (50) Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90(6): 2188-2195. (51) Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83(2): 435-445. (52) Dallaire BK, Deardorff J., White C.A., Dowden S., Varns C., Shen D. et al. Antibody therapy with Rituximab for patients with low-grade Non-Hodgkin's Lymphoma. Onkologie 1999; (22): 184-190. (53) Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91(5): 1644-1652. (54) Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000; 60(24 ): 7170-7176. (55) Nadler LM, Ritz J, Bates MP, Park EK, Anderson KC, Sallan SE et al. Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest 1982; 70(2): 433-442. (56) Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van DJ. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136(6): 1215-1222. (57) Bourget I, Di BW, Breittmayer JP, Grenier-Brossette N, Plana-Prades M, Bonnefoy JY et al. CD20 monoclonal antibodies stimulate extracellular cleavage of the low affinity receptor for IgE (Fc epsilon RII/CD23) in Epstein-Barr-transformed B cells. J Biol Chem 1994; 269(9): 6927-6930. (58) Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC et al. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 1987; 70(2): 418-427. (59) Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol 1996; 105(4): 451-457. (60) Frizzera G, Wu CD, Inghirami G. The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Am J Clin Pathol 1999; 111(1 Suppl 1):S13-S39. (61) Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84(8): 2457-2466. (62) Huhn D, von SC, Wilhelm M, Ho AD, Hallek M, Kuse R et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98(5): 1326-1331. (63) Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes . Proc Natl Acad Sci U S A 1988; 85(1): 208-212. (64) Thevenin C, Lucas BP, Kozlow EJ, Kehrl JH. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem 1993; 268(8): 5949-5956. (65) Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997; 90(10): 3984-3995. (66) Adra CN, Lelias JM, Kobayashi H, Kaghad M, Morrison P, Rowley JD et al. Cloning of the cDNA for a hematopoietic cell-specific protein related to CD20 and the beta subunit of the high-affinity IgE receptor: evidence for a family of proteins with four membrane-spanning regions. Proc Natl Acad Sci U S A 1994; 91(21): 10178-10182. (67) Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF. Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics 2001; 53(5): 357-368. (68) Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989; 337(6203): 187-189. (69) Liang Y, Tedder TF. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 2001; 72(2): 119-127. (70) Di VF, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001; 97(3): 587-600. (71) Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15(9): 450-454. (72) Yokose N, Ogata K, Sugisaki Y, Mori S, Yamada T, An E et al. CD20-positive T cell leukemia/lymphoma: case report and review of the literature. Ann Hematol 2001; 80(6): 372-375. (73) Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol 1996; 106(1): 78-81. (74) Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993; 14(2): 196-204. (75) Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165(11): 6635-6643. (76) Leveille C, AL-Daccak R, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999; 29(1): 65-74. (77) Finn WG, Thangavelu M, Yelavarthi KK, Goolsby CL, Tallman MS, Traynor A et al. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol 1996; 105(4): 458-467. (78) Scott CS, Stark AN, Head C, Roberts BE. Diagnostic features and survival in typical and prolymphocytoid variants of chronic lymphocytic leukemia. Hematol Oncol 1989; 7(2): 175-179.